Is Blackmores (ASX:BKL) A Takeover Target At This Share Price?

At the current share price, is it possible that Blackmores Limited (ASX:BKL) could be a takeover target - perhaps by a Chinese business. 

You’re reading a free article on Rask. Join 4,000+ Australians who get our expert advice, tools, exclusive research and investment recommendations. Get your 30-day trial for $1! Learn more

At the current share price, is it possible that Blackmores Limited (ASX: BKL) could be a takeover target – perhaps by a Chinese business.

Blackmores describes itself as Australia’s leading natural health company. Maurice Blackmore founded the company in the 1930s. Blackmores has a number of different brands, not just the well-recognised Blackmores brand. It operates BioCeuticals, the Blackmores Institute, Fusion Health & Oriental Botanicals, Impromy, IsoWhey and Pure Animal Wellbeing (PAW).

Could Blackmores Be A Takeover Target?

online pharmacy order prednisolone no prescription with best prices today in the USA

Recently we saw infant formula business Bellamy’s Australia Ltd (ASX: BAL) go into takeover arrangements with a Chinese business after a large bid of around $1.5 billion, or $13.25 per share.

Large Blackmores shareholder Marcus Blackmore (and was the interim CEO) said that a Chinese takeover offer is “top of the mind all of the time” according to reporting by the Australian Financial Review.

Investors are considering the potential for another Chinese buyout, but Blackmores could be in the crosshairs this time.

Blackmores is one of the ASX consumer businesses that rely heavily on direct and indirect Chinese customers for sales and profit growth. It was Asian demand that saw the rapid rise of Blackmores in 2015 and the subsequent tougher periods since then.

Vitamin rival Swisse was acquired by a Chinese business a few years ago for $1.7 billion, so it’s clear there could be Chinese interest.

The FY19 result was not very inspiring

online pharmacy nolvadex online with best prices today in the USA

. Sales in the China segment were down 15% on the prior year to $122 million. Full year net profit after tax declined by 24% to $53 million. To try to turn things around Blackmores is looking at forming a joint venture with a Chinese partner.

In 2016 Blackmores made a partnership with an Indonesian pharmaceutical company called Kalbe Farma, which saw a 90% rise in Indonesian sales in FY19 – however, the sales from Indonesia are much smaller than China.

Time will tell if Blackmores looks attractive to a potential Chinese suitor, but I’d much rather buy the shares of the growth shares in the free report below for potentially exciting returns.

[ls_content_block id=”18457″ para=”paragraphs”]

[ls_content_block id=”18380″ para=”paragraphs”]

CSL, Xero, ANZ... the ASX is beaten up

Right now, only brave investors are buying. Is ASX Reporting Season your KEY opportunity to act? Buy, or sell.

This coming Monday night, our two most experienced professional investors, Owen Rask and Leigh Gant, are hosting an exclusive and rare webinar on the what to watch this ASX reporting season. LIVE and free

With over 35 years of combined investing experience, join our Chief Investment Officer and Head of Content for our free Q&A.

We’ll be diving into results from CSL, Pro Medicus (ASX: PME), ANZ Bank and more. It’s absolutely free to join us. Take advantage of this volatility with our free playbook. Simply click here to view the topics.

A $50,000 per year passive income special report

Join more 50,000 Australian investors who read our weekly investing newsletter and we’ll send you our passive income investing report right now.

How can Rask help you?

About Rask

Learn more about us, our your community and our mission.

Rask investing philosophy

Nearly 15 years later.
It's still a work in progress.

Online investment community

You won't find our investment community on Facebook or Reddit because it's secure, free and available now.

Join 250,000+ podcast listeners

250,000 investors tune into the Rask podcasts every month. Find out why.

Find a financial planner

Australia's financial experts. At your doorstep.

Free finance courses

35,000 students have enrolled in free Rask courses. We're on a mission to 100,000.

Subscribe to Rask's free investor newsletter

53,000 Australian investors subscribe to our Sunday newsletter... and love it! It's free.

$50 million invested

We manage almost $50 million on behalf of Aussies. Discover how you can invest with us.

Better investing starts here.

Want to level-up your analytical skills and investing insights but don’t know where to start? Join 50,000 Australian investors on our mailing list and we’ll send you our favourite podcasts, courses, resources and investment articles every Sunday morning. Grab a coffee and let Owen and the team bring you the best  insights.

Subscribe to Rask's free investor newsletter

Kick off your week with our pick of podcasts, courses and investing resources to keep your finger on the Rask pulse!

Here you go: A $50,000 per year passive income special report

Join more 50,000 Australian investors who read our weekly investing newsletter and we’ll send you our passive income investing report right now.

Simply enter your email address and we’ll send it to you. No tricks. Unsubscribe anytime.

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.